-
Mashup Score: 3Post-Hoc: AI bio needs to heed the overhyped history of CRISPR - 2 month(s) ago
Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO’s disease cure claims.
Source: endpts.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
The FDA’s Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer.
Source: endpts.comCategories: General Medicine NewsTweet-
@US_FDA #adcomm narrowly votes against @UroGenPharma ’s bladder cancer drug mitomycin, calls for RCTs https://t.co/DKeNonp5R5 via @ZacharyBrennan
-
-
Mashup Score: 2FDA asks Covid vaccine makers to add more myocarditis data to labels - 2 month(s) ago
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young men.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
FDA asks Covid vaccine makers to add more myocarditis data to labels https://t.co/PnzvHg6RaL
-
-
Mashup Score: 2FDA asks Covid vaccine makers to add more myocarditis data to labels - 2 month(s) ago
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young men.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
FDA asks Covid vaccine makers to add more myocarditis data to labels https://t.co/PnzvHg6RaL
-
-
Mashup Score: 1In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines - 2 month(s) ago
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines that he feels will counteract existing “dogma.”
Source: endpts.comCategories: General Medicine NewsTweet-
In his first major @US_FDA policy rollout, Prof @VPrasadMDMPH looks to challenge existing 'dogma' on Covid vaccines https://t.co/rQqvDusM6k via @maxonwifi
-
-
Mashup Score: 11
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Source: endpts.comCategories: General Medicine NewsTweet-
Anyone with any interest in biotech should read this @endpts survey and see what biotech CEOs are saying. Trump 2.0 is having a profound effect — and it’s unintentional. More collateral damage. https://t.co/iTXIYDnq0z
-
-
Mashup Score: 11
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Source: endpts.comCategories: General Medicine NewsTweet-
Anyone with any interest in biotech should read this @endpts survey and see what biotech CEOs are saying. Trump 2.0 is having a profound effect — and it’s unintentional. More collateral damage. https://t.co/iTXIYDnq0z
-
-
Mashup Score: 53Why Regeneron is buying 23andMe - 2 month(s) ago
Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the 23andMe deal as worthwhile.
Source: endpts.comCategories: General Medicine NewsTweet-
Regeneron's 23andMe buyout is the best possible outcome. A Big Pharma would just bobble it, then watch it die. REGN is far more purposeful and directed. They get it cheap, keep their eyes on the ball and manage things. I like it. https://t.co/PwOyG1zOd8
-
-
Mashup Score: 1Regeneron plans to buy 23andMe for $256M - 2 month(s) ago
Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe’s bankruptcy filing and recent struggles.
Source: endpts.comCategories: General Medicine NewsTweet-
Regeneron plans to buy 23andMe for $256M - https://t.co/MH3w8wtr6v
-
-
Mashup Score: 5Novo Nordisk CEO to step down, timeline for successor unknown - 2 month(s) ago
Novo Nordisk CEO Lars Fruergaard Jørgensen will step down amid market challenges and a clinical disappointment for CagriSema.
Source: endpts.comCategories: General Medicine NewsTweet-
Stunning success, sky high expectations before a remorseless rival drives a dagger through a CEO's career. Novo goes inside for its big promotions, will it do anything differently this time? (Cause the CEO alone ain't going to change this narrative.) https://t.co/urAZULPs0m
-
AI bio needs to heed the overhyped history of CRISPR https://t.co/F22wdo03t7 via @AndrewE_Dunn